NAV-201 is a small-molecule compound that  binds to CD16/Fc Receptor and activates NK cells, which go on to kill tumor cells (figure). NAV-201 can restore NK cell activity in the presence of immunosuppressive HIO factors. 
NAV-201 has been identified from a library of natural compounds by using our proprietary BRITE screening platforms and has been enhanced by structure-activity relationship analyses. NAV-201 is being developed for treating cancers immunosuppressed by HIO factors.